Wallaby Medical

What Wallaby Medical does

Wallaby Medical is a multinational neurovascular medical device company that develops, manufactures, and commercializes interventional products for the treatment of both ischemic and hemorrhagic stroke. Founded in December 2015 and headquartered in Laguna Hills, California with operational headquarters in Shanghai, the company built its initial franchise on the Avenir Coil System for endovascular embolization of intracranial aneurysms and the Esperance family of aspiration catheters and distal access catheters for acute ischemic stroke treatment. Following the April 2022 acquisition of Germany's phenox GmbH (including femtos GmbH) for approximately EUR 500 million, Wallaby expanded into a comprehensive neurovascular portfolio spanning flow diverters (p64/p48), stent retrievers (pRESET), stent systems (pEGASUS HPC), microcatheters (pNOVUS), and balloon/guide catheters, operating as WallabyPhenox Group with 700+ employees, 5 R&D centers, and 3 production bases.

The company's core technology centers on proprietary materials science and mechanical engineering, including HPC (Hydrophobic Polymer Coating) for antithrombogenic implant enhancement, super-elastic nitinol lasso detachment zone technology, multi-filar coil construction, dual-layer nitinol aspiration catheter architecture, and femto-second laser stent manufacturing. Products hold regulatory clearances across FDA 510(k), CE Mark, NMPA, PMDA, and Korea MFDS, with Avenir approved in 40+ countries and the combined portfolio marketed in 60+ countries.

Wallaby generates revenue through B2B hardware sales to comprehensive stroke centers, academic medical centers, and neurovascular surgery departments. The go-to-market model is hybrid: direct enterprise sales forces in the US and China, combined with exclusive distribution partnerships in international markets, notably a 10-year exclusive agreement with Japan Lifeline covering 11 products in Japan. The company also distributes Brainomix's AI-powered e-Stroke imaging software in Greater China as a complementary offering to its device portfolio. Pricing is quote-based through hospital procurement rather than publicly disclosed.

Name

Wallaby Medical

Legal name

Wallaby Medical Holding, Inc.

Website

https://wallabymedical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Wallaby Medical is a global neurovascular medical device company developing interventional products for ischemic and hemorrhagic stroke treatment, serving comprehensive stroke centers and hospitals in 60+ countries through direct sales and distribution partnerships.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Neurovascular medical devices
• Stroke treatment products
• Intracranial aneurysm coils
• Mechanical thrombectomy devices
• Neurointerventional catheters

Headquarters

HQ city

Laguna Hills

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Neurovascular Medical Device Sales: Wallaby Medical generates revenue through the sale of neurovascular interventional products including coil systems, aspiration catheters, stent retrievers, flow diverters, and microcatheters. Products are sold through direct sales in U.S. and China markets, and through distribution partners in Japan, Europe, and other international markets. The company operates with 5 R&D centers and 3 production bases supporting global commercialization.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Wallaby Medical is a neurovascular medical device manufacturer that develops, produces, and sells interventional devices for the treatment of both ischemic and hemorrhagic stroke. Its portfolio spans embolic coils for intracranial aneurysm embolization, aspiration catheters and stent retrievers for mechanical thrombectomy, flow diverters, stent systems, distal access and guide catheters, and microcatheters. The company also distributes Brainomix's e-Stroke AI imaging software in Greater China, providing hospitals and stroke centers with an end-to-end solution for neurovascular intervention.

Product overview

Wallaby Medical is a multinational neurovascular medical technology company offering a comprehensive portfolio of stroke treatment products. The portfolio includes the Avenir® Coil System for treating intracranial aneurysms (hemorrhagic stroke) and the Esperance™ family of aspiration catheters and distal access catheters for ischemic stroke treatment. Following the April 2022 acquisition of phenox GmbH, the company expanded to include phenox's p64/p48 flow diverters, pRESET thrombectomy devices, pEGASUS stent system, pCONUS bifurcation aneurysm device, and other neurovascular products. The combined portfolio covers both ischemic and hemorrhagic stroke treatment, including access and support devices. Wallaby Medical also distributes Brainomix's e-Stroke AI imaging software (e-ASPECTS, e-CTA, e-CTP modules) in Greater China. Products are sold in over 60 countries with regulatory approvals including FDA 510(k), CE Mark, NMPA, and PMDA.

Differentiator

Problem solved

Functional benefit

Brands

• Avenir Coil System: Technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities
• Esperance Aspiration Catheter
• Esperance Distal Access Catheter
• pRESET
• p64/p48 Flow Diverters
• pEGASUS Stent System
• pCONUS Stent Assist Device
• pITA Neuro PTA Balloon Catheter
• pRELAX
• pNOVUS Microcatheter
• Pilote Distal Access Guide Catheter

Products and services

• Avenir Coil System A technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities. Features complex framing coils, ultra-soft finishing coils, and instant mechanical detachment mechanism with no external energy source required. The integrated mechanical detachment uses proprietary multi-filar technology and a super-elastic nitinol lasso detachment zone to minimize microcatheter kick-out during intracranial navigation. Approved in over 40 countries.
• Esperance 5F/6F Aspiration Catheter Aspiration catheter for ischemic stroke treatment designed for first-pass recanalization. Features ultra-thin-walled dual-layer construction with 0.071 inch inner lumen, 14 transition zones for flexibility and support, PTFE-lined smooth inner surface, and dual-reinforced nitinol coil/braid for kink resistance. Achieves 65% first-pass recanalization rate (57% higher than COMPASS study) and 62.3% 90-day mRS (0-2) outcomes.
• Esperance Distal Access Catheter Distal access catheter approved in China for delivery assistance during ischemic stroke and hemorrhagic stroke procedures. Used to deliver therapeutic devices to target locations during neurovascular interventions.
• pRESET Thrombectomy Device Stentriever for mechanical thrombectomy in patients with acute ischemic stroke due to large vessel occlusion. Designed for easy use and quick deployment. FDA 510(k) cleared in the U.S. and available in Europe for over 10 years.
• p64/p48 Flow Modulation Device Flow diverters for the treatment of intracranial aneurysms. The p64 and p48 devices are approved in Europe for modulating blood flow into aneurysms, part of the phenox GmbH product portfolio acquired by Wallaby Medical in 2022.
• pEGASUS HPC Stent System Laser-cut, open-cell stent device with antithrombogenic HPC (Hydrophilic Polymer Coating) proprietary coating technology. Stent assist device for neurovascular interventions, globally launched in September 2022 as the first such device with HPC coating.
• pCONUS Stent Assist Device Stent assist device specifically designed for the treatment of bifurcation aneurysms. Part of phenox's portfolio for treating complex aneurysm anatomies acquired by Wallaby Medical.
• pITA Neuro PTA Balloon Catheter Neuro PTA (percutaneous transluminal angioplasty) balloon catheter for neurovascular procedures. Part of phenox's product portfolio acquired by Wallaby Medical.
• pRELAX Vasospasm Treatment Device Device for the treatment of cerebral vasospasm. Part of phenox's neurovascular product portfolio acquired by Wallaby Medical in April 2022.
• Pilote Distal Access Guide Catheter Long sheath for distal access during neurovascular procedures. Used in combination with other Wallaby Medical products for stroke treatment interventions, including with the Avenir Coil System, Esperance Distal Access Catheter, and pNOVUS 17 Microcatheter.
• pNOVUS 17 Microcatheter Microcatheter independently developed by Wallaby Medical, the third member of the pNOVUS family. Approved by NMPA (China), FDA 510K (USA), and PMDA (Japan). Used for delivering therapeutic devices during neurovascular procedures in combination with Pilote Distal Access Guide Catheter, Esperance Distal Access Catheter, and Avenir Coil System.
• Avenir Plus Coil System An expanded addition to the Avenir Coil System independently developed by Wallaby Medical, including 65 new sizes with redesigned primary wire and coil size for endovascular embolization of intracranial aneurysms. Approved by NMPA in China.
• Brainomix e-Stroke Suite AI-powered stroke imaging software platform distributed by Wallaby Medical in Greater China through partnership with Brainomix Limited. Includes e-ASPECTS (automated ASPECTS scoring from CT scans), e-CTA (CT angiography analysis), and e-CTP (CT perfusion imaging) modules. Enables real-time interpretation of brain scans to guide stroke treatment and transfer decisions, complementing Wallaby's neurovascular device portfolio.

Quantifiable outcome

• 65% first-pass recanalization rate with Esperance 6F aspiration catheter (57% higher than COMPASS study)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• Japan Lifeline Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 22 August 202210-year exclusive distribution agreement covering 11 neurovascular products in Japan market. Japan Lifeline launched Avenir Coil System in April 2022 and expanded to distribute Esperance Aspiration Catheter, Balloon Guide Catheter, Microcatheter, and phenox products including p64/p48 flow diverters and pRESET stent retrievers.
• phenox GmbHflagshipStrategic or Co-development Partner · 21 April 2022Wallaby Medical acquired phenox GmbH including femtos for approximately EUR 500 million. phenox is a German-based global innovation and technology leader in neurovascular space with products in over 45 countries. Acquisition enables combined company to become global leader in neurovascular technologies.
• Brainomix LimitedcoreGTM or Marketing Partner · 26 August 2021Distribution agreement for Brainomix e-Stroke AI software platform in Greater China. e-Stroke provides real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, complementing Wallaby's neurovascular device portfolio.
• Chinese Association of Cerebrovascular DiseasesminorStrategic or Co-development Partner · 1 May 2021Strategic cooperation signed for cerebrovascular disease industry technology innovation in China.
• Beijing Cerebrovascular Disease Industry Technology Innovation Strategic AllianceminorStrategic or Co-development Partner · 1 May 2021Strategic cooperation for industry technology innovation and development in Beijing cerebrovascular disease sector.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Penumbra: Penumbra's neurovascular business (Indigo aspiration system, RED reperfusion catheters, Penumbra System) directly competes with Wallaby's Esperance aspiration catheter and pRESET stentriever in mechanical thrombectomy. Both target comprehensive stroke centers with hardware sales models.
• Acandis: Germany-based Acandis develops and markets neurovascular devices including stent retrievers (APERIO) and coil systems that overlap with WallabyPhenox's phenox-derived portfolio. Comparable scale and European market focus.
• MicroPort NeuroTech: MicroPort's neurovascular subsidiary is the closest Chinese-headquartered peer to Wallaby, competing in flow diverters (Tubridge), coils, and stent retrievers. Direct overlap in product portfolio and target geography (China comprehensive stroke centers).
• Balt Group: France-based Balt is a neurovascular specialist with a broad portfolio of coils, flow diverters, and stents, competing with WallabyPhenox in intracranial aneurysm treatment across European and international markets.

Emerging players

• Imperative Care: US-based Imperative Care is an emerging neurovascular company developing next-generation stroke intervention technologies (Zoom aspiration, Symphony thrombectomy), competing with WallabyPhenox in US comprehensive stroke centers.
• Rapid Medical: Israel-based Rapid Medical is a smaller, focused neurovascular player with TIGERTRIEVER stentriever and COMANECI embolization assist device. Emerging competitor with differentiated adjustable technology targeting the same stroke center customers.

Broad incumbents

• Johnson & Johnson MedTech (Cerenovus): Cerenovus (J&J MedTech) markets the Embotrap stentriever, Pipeline Embolization Device, and other neurovascular products that compete head-on with WallabyPhenox's Avenir coils, pRESET stentriever, and p64 flow diverters.
• Stryker (Stryker Neurovascular): Stryker's Neurovascular division (acquired Concentric, formerly Target Therapeutics) offers a broad neurovascular portfolio including the AXS Catalyst aspiration catheters and Trevo stentriever — directly overlapping with WallabyPhenox's stroke intervention line, but as part of Stryker's much larger diversified medical device portfolio.
• Medtronic (Neurovascular): Medtronic's Neurovascular business offers Solitaire stent retriever, Riptide aspiration, and Pipeline flow diverters — directly overlapping with WallabyPhenox across ischemic and hemorrhagic stroke. Medtronic is the broad incumbent with the deepest hospital relationships and largest salesforce.

Regional players

• Kaneka (Neurovascular Division): Japan-headquartered Kaneka operates a neurovascular division selling coils and other devices in the Japanese market, partially overlapping with WallabyPhenox's Japan Lifeline-distributed portfolio in the same geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wallaby Medical